Management of hypertension in peripheral arterial disease: does the choice of drugs matter?

[1]  T. Nursal,et al.  The prevalence and clinical predictors of incidental atherosclerotic renal artery stenosis. , 2009, European journal of radiology.

[2]  Jeroen J. Bax,et al.  Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. , 2007, Journal of the American Society of Nephrology : JASN.

[3]  N. Cook,et al.  Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP) , 2007, BMJ : British Medical Journal.

[4]  Y. Ostchega,et al.  Prevalence of Peripheral Arterial Disease and Risk Factors in Persons Aged 60 and Older: Data from the National Health and Nutrition Examination Survey 1999–2004 , 2007, Journal of the American Geriatrics Society.

[5]  M. Flather,et al.  Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[6]  J. Powell Intermittent claudication: a plea for guidelines for medical management. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[7]  J. Laragh,et al.  Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial , 2006, Journal of hypertension.

[8]  L. Hunyady,et al.  Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. , 2006, Molecular endocrinology.

[9]  Jeroen J. Bax,et al.  Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. , 2006, Journal of the American College of Cardiology.

[10]  P. Kowey,et al.  Predictors of adverse outcome among patients with hypertension and coronary artery disease. , 2006, Journal of the American College of Cardiology.

[11]  S. Yusuf,et al.  Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. , 2004, European heart journal.

[12]  J F Potter,et al.  Extract from : , 2009 .

[13]  P. Ridker,et al.  Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. , 2004, Archives of internal medicine.

[14]  S. Yusuf,et al.  Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease , 2004 .

[15]  N. Toda Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics , 2003 .

[16]  E. Boerwinkle,et al.  Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study , 2003, Vascular medicine.

[17]  D. Legemate,et al.  Effect of β-blockers on peripheral skin microcirculation in hypertension and peripheral vascular disease , 2003 .

[18]  P. Mehler,et al.  Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes , 2003, Circulation.

[19]  J. Östergrena,et al.  Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease , 2003 .

[20]  G. Lip,et al.  Treatment of hypertension in peripheral arterial disease. , 2003, The Cochrane database of systematic reviews.

[21]  N. Toda Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. , 2003, Pharmacology & therapeutics.

[22]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[23]  Jeroen J. Bax,et al.  Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. , 2001, European heart journal.

[24]  P. Pattynama,et al.  Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? , 2001, Kidney international.

[25]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[26]  M. Criqui,et al.  Peripheral arterial disease detection, awareness, and treatment in primary care. , 2001, JAMA.

[27]  A. Hofman,et al.  Determinants of peripheral arterial disease in the elderly: the Rotterdam study. , 2000, Archives of internal medicine.

[28]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[29]  W. Mali,et al.  Angiotensin Converting Enzyme Inhibitor-Induced Renal Dysfunction in Atherosclerotic Renovascular Disease , 1999 .

[30]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[31]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[32]  D C Hadorn,et al.  Rating the quality of evidence for clinical practice guidelines. , 1996, Journal of clinical epidemiology.

[33]  M. Olsen,et al.  Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. , 1996, Journal of human hypertension.

[34]  F P Cappuccio,et al.  Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. , 1994, The American journal of medicine.

[35]  L. Ramsay,et al.  beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. , 1991, BMJ.

[36]  Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. , 1991, Archives of internal medicine.

[37]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[38]  J. Brown,et al.  Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease. , 1988, Journal of human hypertension.

[39]  G. Williams,et al.  NIFEDIPINE AND NOCTURIA , 1986, The Lancet.